Recalls and manufacturing woes hit J&J sales in Q4
This article was originally published in Scrip
Executive Summary
The severe impact of recalls of certain OTC medicines and the suspension of manufacturing at one of its facilities has resulted in J&J reporting a significant drop in sales by 5.5% to $15.6 billion for the fourth quarter of 2010, "a lower level of sales than expected", the company conceded in a conference call.